Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.45 |
| ▸ | CDK9 | P50750 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.45 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31355480 | 1.00 | KMT2A (0.57) | KMT2AMEN1MAPK10GFERKDR | |
| SCHEMBL31355479 | 1.00 | KMT2A (0.57) | KMT2AMEN1MAPK10GFERKDR | |
| SCHEMBL3628141 | 0.89 | MEN1 (0.47) | KMT2AMEN1MAPK10GFERKDR | |
| SCHEMBL4630887 | 0.87 | GSK3A (0.53) | KDRSMN1; SMN2GSK3ACDK9CDK5 | |
| Hydrochloric Acid SCHEMBL7857018 | 0.84 | GSK3A (0.51) | KDRSMN1; SMN2GSK3ACDK9CDK5 | |
| SCHEMBL221242 | 0.84 | KMT2A (0.76) | KMT2AMEN1MAPK10GFERKDR | |
| SCHEMBL29391624 | 0.84 | KMT2A (0.76) | KMT2AMEN1MAPK10GFERKDR | |
| SCHEMBL6574416 | 0.82 | KMT2A (0.73) | KMT2AMEN1MAPK10GFERKDR | |
| SCHEMBL11133606 | 0.82 | KMT2A (0.73) | KMT2AMEN1MAPK10GFERKDR | |
| SCHEMBL4243882 | 0.82 | KMT2A (0.73) | KMT2AMEN1MAPK10GFERKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719421-A1 | COMBINATION THERAPY COMPRISING KIT INHIBITORS FOR USE IN THE TREATMENT OF CANCER | IDRX, INC. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250270190-A1 | KIT INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-08-28 | — | — | US | disclosed |
| EP-4511366-A1 | KIT INHIBITORS | Blueprint Medicines Corporation (US) | 2025-02-26 | — | — | EP | disclosed |
| WO-2024249855-A1 | COMBINATION THERAPY COMPRISING KIT INHIBITORS FOR USE IN THE TREATMENT OF CANCER | IDRX, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| WO-2023205226-A1 | KIT INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-10-26 | — | — | WO | disclosed |
| US-11691986-B2 | PTEFB inhibiting macrocyclic compounds | BAYER AKTIENGESELLSCHAFT (DE) | 2023-07-04 | — | — | US | disclosed |
| US-20220281892-A1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-08 | — | — | US | disclosed |
| US-20220059772-A1 | COMPOUNDS, INFRARED ABSORBERS, INFRARED ABSORBING/BLOCKING FILMS, PHOTOELECTRIC DEVICES, SENSORS, AND ELECTRONIC DEVICES | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2022-02-24 | — | — | US | disclosed |
| US-11254690-B2 | PTEFb inhibiting macrocyclic compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-02-22 | — | — | US | disclosed |
| US-11242356-B2 | PTEFb inhibiting macrocyclic compounds | BAYER AKTIENGESELLSCHAFT (DE) | 2022-02-08 | — | — | US | disclosed |
| CN-104918932-A | N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfoximine group | Bayer Pharma AG | 2015-09-16 | — | — | CN | disclosed |
| EP-2909200-A2 | N-(PYRIDIN-2-YL)PYRIMIDIN-4-AMINE DERIVATIVES CONTAINING A SULFONE GROUP | Bayer Pharma Aktiengesellschaft (DE) | 2015-08-26 | — | — | EP | disclosed |
| EP-2909200-A2 | N-(PYRIDIN-2-YL)PYRIMIDIN-4-AMINE DERIVATIVES CONTAINING A SULFONE GROUP | Bayer Pharma Aktiengesellschaft (DE) | 2015-08-26 | — | — | EP | disclosed |
| WO-2015001021-A1 | SULFOXIMINE SUBSTITUTED 5-FLUORO-N-(PYRIDIN-2-YL)PYRIDIN-2-AMINE DERIVATIVES AND THEIR USE AS CDK9 KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-01-08 | — | — | WO | disclosed |
| WO-2014060493-A3 | N-(PYRIDIN-2-YL)PYRIMIDIN-4-AMINE DERIVATIVES CONTAINING A SULFONE GROUP | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014076111-A1 | N-(PYRIDIN-2-YL)PYRIMIDIN-4-AMINE DERIVATIVES CONTAINING A SULFOXIMINE GROUP | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014076111-A1 | N-(PYRIDIN-2-YL)PYRIMIDIN-4-AMINE DERIVATIVES CONTAINING A SULFOXIMINE GROUP | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014060493-A2 | N-(PYRIDIN-2-YL)PYRIMIDIN-4-AMINE DERIVATIVES CONTAINING A SULFONE GROUP | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014060493-A2 | N-(PYRIDIN-2-YL)PYRIMIDIN-4-AMINE DERIVATIVES CONTAINING A SULFONE GROUP | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-04-24 | — | — | WO | disclosed |
| WO-2009029617-A1 | DIARYLAMINE-SUBSTITUTED QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11242356-B2 | PTEFb inhibiting macrocyclic compounds | PCLAF, PPIB, RHEB | KMT2A 3422/4885MEN1 647/4885MAPK10 896/4885 |
| US-20220281892-A1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | PCLAF, PKD1, RHEB | KMT2A 3620/4885MEN1 803/4885MAPK10 751/4885 |
| US-20250270190-A1 | KIT INHIBITORS | KIT, ABL1, APC | KMT2A 232/4885MEN1 854/4885MAPK10 114/4885 |
| US-20220059772-A1 | COMPOUNDS, INFRARED ABSORBERS, INFRARED ABSORBING/BLOCKING FILMS, PHOTOELECTRIC DEVICES, SENSORS, AND ELECTRONIC DEVICES | CRY1, SCN1B, CCNT1 | KMT2A 3047/4885MEN1 218/4885MAPK10 2359/4885 |
| US-11254690-B2 | PTEFb inhibiting macrocyclic compounds | PCLAF, PPIB, RHEB | KMT2A 3422/4885MEN1 647/4885MAPK10 896/4885 |
| US-11691986-B2 | PTEFB inhibiting macrocyclic compounds | PCLAF, PPIB, RHEB | KMT2A 3422/4885MEN1 647/4885MAPK10 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.